Filing Flows › iBio (IBIO) › Recalls, complaints & regulation
iBio (IBIO): clinical trials
iBio (IBIO) beyond its filings: 2 active clinical trials.
iBio's latest quarter
iBio, Q1 FY26: revenue $100K, net loss $5.7M, operating cash flow −$5.7M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does iBio have?
2 active studies on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.